arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aptevo Therapeutics Inc.

APVO
$1.25 ▼ -0.10 (-7.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
45 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aptevo Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -84.3% ↘
FCF / Share $-4.56 ↗
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-6.70M
↓ -4.5% —
Operating Margin Operating profit as % of sales
-180.2%
↓ -63.5% —
FCF / Share Free cash flow per share
$-4.56
↑ +39.3% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
5
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 12 years · 45 quarters